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Abstract: Utilization of gene silencing effectors, such as microRNA (miRNA) and small 
hairpin RNA (shRNA), provides a powerful new strategy for human skin care in vivo, 
particularly for hyperpigmentation treatment and aging prevention. In this study, tyrosinase 
(Tyr), the rate-limiting enzyme of melanin (black pigment) biosynthesis, was served as a 
target for treatment of hyperpigmentation in mouse and human skins. There are over 54 native 
microRNA capable of silencing human tyrosinase for skin whitening and lightening. To 
this, we have designed a mir-434-5p homologue and used it to successfully demonstrate 
the feasibility of miRNA-mediated skin whitening and lightening in vitro and in vivo. 
Under the same experimental condition in the trials, Pol-II-directed intronic mir-434-5p 
expression did not cause any detectable sign of cytotoxicity, whereas siRNAs targeting 
the same sequence often induced certain nonspeciﬁ  c mRNA degradation as previously 
reported. Because the intronic miRNA-mediated gene silencing pathway is tightly regulated 
by multiple intracellular surveillance systems, including Pol-II transcription, RNA splic-
ing, exosomal digestion and nonsense-mediated RNA decay (NMD), the current ﬁ  ndings 
underscore the fact that intronic miRNA agents, such as manually re-designed mir-434-5p 
homologues, are effective, target-speciﬁ  c and safe to be used for skin whitening without 
any detectable cytotoxic effect. Given that the human skins also express a variety of other 
native miRNAs, we may re-design these miRNAs based on their individual functions for 
skin care, which may provide signiﬁ  cant insights into areas of opportunity for new cosmetic 
and/or therapeutical applications.
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Introduction
Prevention of hyperpigmentation (ie, sun-burn) and aging is the key means for having 
healthy skins. However, many of the skin pigmentation and aging processes are asso-
ciated with personal gene activities. For example, tyrosinase (Tyr), a melanocytic 
membrane-bound glycoprotein, is the rate-limiting enzyme critical for melanin (black 
pigment) biosynthesis in skins and hairs, while hyaluronidase (Hyal) often causes skin 
wrinkle by degrading subcutaneous hyaluronan (HA), the major antiaging extracel-
lular matrix in skins. Therefore, a good skin care can be achieved by suppressing the 
activities of these enzymes.
Among a variety of currently available skin whitening and lightening products, many 
chemical and naturally extracted agents have been applied to inhibit tyrosinase function, 
using materials such as hormone-derived inhibitory oligopeptides, hydroxytetronic acid 
derivatives, benzoyl compounds, hydroquinone compositions, alcohol diol and triol ana-
logues, kojic acid derivatives, ascomycete-derived enzymes, and plant extracts. Although 
these cosmetic agents work well in vitro, only a few of them, such as hydroquinone and 
its derivatives, are able to induce decent hypopigmenting effects in clinical trials (Solano 
et al 2006). Nevertheless, all hydroquinone derivatives leading to a reactive quinone are 
putative cytotoxic agents. Thus, the gap between in vitro and in vivo studies suggests 
that innovative strategies are needed for validating their safety and efﬁ  cacy.Clinical, Cosmetic and Investigational Dermatology 2008:1 20
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With the advance of recent RNA interference (RNAi) 
technologies, novel small RNA agents have been found to 
mediate more potent effects in targeted gene suppression. 
These include double-stranded short interfering RNA 
(eg, dsRNA/siRNA) and doxyribonucleotidylated-RNA 
interfering molecules (eg, D-RNAi) (Fire et al 1998; Elbashir 
et al 2001; Lin and Ying 2001). Conceivably, these small 
RNA agents may be used to develop new cosmetic designs 
and products for skin care. In principle, the RNAi mechanism 
elicits a post-transcriptional gene silencing (PTGS) phenom-
enon capable of inhibiting speciﬁ  c gene function with high 
potency at a few nanomolar dosage, which has been proven 
to be effective longer and much less toxic than conventional 
gene-knockout methods using antisense oligonucleotides or 
small molecule chemical inhibitors (Lin and Ying 2001). As 
reported in many previous studies, the siRNA-induced gene 
silencing effects may last over one week, while the D-RNAi 
effects can even sustain up to one month after one treatment 
(Grant 1999; Elbashir et al 2001; Lin and Ying 2001; Lin and 
Ying 2004). These siRNA/D-RNAi agents evoke a series of 
intracellular sequence-speciﬁ  c mRNA degradation and/or 
translational suppression processes, affecting all highly 
homologous gene transcripts, namely co-suppression. It 
has been observed that such co-suppression results from the 
generation of small RNA products (21–25 nucleotide bases) 
by the enzymatic activities of RNaseIII endoribonucleases 
(Dicer) and/or RNA-directed RNA polymerases (RdRp) on 
aberrant RNA templates, which are usually the derivatives 
of foreign transgenes or viral genomes (Grant 1999; Elbashir 
et al 2001; Lin and Ying 2001).
Limitations of siRNA/shRNA-based 
gene silencing agents
Although the modern RNAi technologies may offer a new 
avenue for suppressing unwanted gene function in skins, the 
applications thereof have not been demonstrated to work 
consistently and safely in higher vertebrates, including ﬁ  sh, 
avian, mammal and human. For example, almost all of the 
current siRNA agents are based on a double-stranded RNA 
(dsRNA) conformation, which has been shown to cause inter-
feron-mediated nonspeciﬁ  c RNA degradation in vertebrates 
(Stark et al 1998; Elbashir et al 2001). Such an interferon-
mediated cytotoxic response reduces the target speciﬁ  city 
of siRNA-induced gene silencing effects and often results 
in global RNA degradation in vertebrate cells. Particularly 
in mammalian cells, it has been noted that the RNAi effects 
are disturbed when the siRNA/dsRNA size is longer than 
25 basepairs (bp) (Elbashir et al 2001). Transfection of 
siRNA or small hairpin RNA (shRNA) sized less than 25 bp 
may not completely overcome such a problem, because 
both Sledz and colleagues (2003) and Lin and Ying (2004) 
have reported that the high dosage of siRNAs and shRNAs 
(such as 250 nM in human T cells) is able to cause strong 
cytotoxic effects similar to those of long dsRNAs. This 
toxicity is due to their double-stranded RNA conformation, 
which activates the interferon-mediated nonspeciﬁ  c RNA 
degradation and programmed cell death through the 
activation of cellular PKR and 2-5A signaling pathways. It 
has been well established that interferon-activated protein 
kinase PKR can trigger cell apoptosis, while the activation 
of interferon-induced 2’,5’-oligoadenylate synthetase (2-5A) 
system leads to extensive cleavage of single-stranded RNAs, 
such as mRNAs (Stark 1998). Both PKR and 2-5A systems 
contain dsRNA-binding motifs, which possess high afﬁ  nity 
to the double-stranded RNA conformation. Further, the 
most difﬁ  cult problem is that these small siRNA/shRNA 
agents are not stable enough to be maintained at an optimal 
dose in vivo due to the abundant RNase activities in higher 
vertebrates (Brantl 2002).
As the RNAi effects are naturally caused by the produc-
tion of small RNA products (21–25 nucleotide bases) from 
a transcriptional template derived from foreign transgenes or 
viral genomes (Grant 1999; Lin and Ying 2001), the recent 
utilization of Pol-III-directed siRNA/shRNA expression 
vectors has been shown to offer relatively stable RNAi effects 
in vivo (Tuschl 2002). Although previous studies using such 
a vector-based siRNA approach have demonstrated constant 
gene silencing effects (Lee et al 2002; Miyagishi and Tira 
2002; Paul et al 2002), their strategies failed to focus the 
RNAi effects on a targeted cell or tissue population because 
of the ubiquitous existence of type III RNA polymerase 
(Pol-III) activity. Pol-III promoters, such as U6 and H1, 
are activated in almost all cell types, making tissue-speciﬁ  c 
gene silencing impossible. Moreover, because the leaky 
read-through activity of Pol-III transcription often occurs 
on a short DNA template in the absence of proper termina-
tion, large RNA products longer than desired 25 bps can 
be synthesized and cause unexpected interferon-mediated 
cytotoxicity (Gunnery et al 1999; Schramm 2002). Such 
a problem can also result from the competitive conﬂ  ict 
between the Pol-III promoter and another vector promoter 
(ie, LTR and CMV promoters). Furthermore, it is recently 
noted that high siRNA/shRNA concentrations generated 
by the Pol-III-directed RNAi systems can over-saturate the 
cellular native microRNA (miRNA) pathway and thus cause 
global miRNA inhibition and cell death (Grimm et al 2003). Clinical, Cosmetic and Investigational Dermatology 2008:1 21
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These disadvantages discourage the use of Pol-III-based 
RNAi vector systems in health care. In order to improve the 
delivery stability, targeting speciﬁ  city and safety aspects of 
modern RNAi technologies for healthy skin care, a better 
transduction and maintenance strategy is highly desired.
Intronic microRNA-mediated 
RNAi mechanism
Research based on gene transcript (eg, mRNA), an assembly 
of protein-coding exons, is fully described throughout the 
literature, taking the fate of spliced noncoding introns to be 
completely digested for granted (Nott et al 2003). Is it true 
that the intronic portion of a gene is destined to be a genetic 
waste without function or is there an yet undiscovered func-
tion for it? Recently, this misconception was corrected by the 
discovery of intronic microRNA (miRNA) (Lin et al 2003; 
Ying and Lin 2004; Ying and Lin 2005). Intronic miRNA 
is a new class of small single-stranded regulatory RNAs 
derived from the introns, which are spliced out of the precur-
sor messenger RNA (pre-mRNA) of the encoding gene and 
further processed into small mature miRNAs (Lin et al 2003). 
A miRNA is usually about 18–27 nucleotides (nt) in length 
and is capable of either directly degrading its messenger RNA 
(mRNA) target or suppressing the protein translation of its 
targeted mRNA, depending on the complementarity between 
the miRNA and its target. In this way, the intronic miRNA is 
functionally similar to previously described siRNA/shRNA, 
but differs from them in the requirement of intracellular type 
II RNA polymerase (Pol-II) transcription and RNA splicing 
processes for its biogenesis (Lin et al 2003). In addition, since 
introns naturally contain multiple translational stop codons 
for recognition by the intracellular nonsense-mediated decay 
(NMD) system (Zhang et al 1994; Danin-Kreiselman et al 
2003), most of the unstructured intron sequences can be 
quickly degraded after RNA splicing to prevent excessive 
accumulation, which is toxic to the cells. It has been deter-
mined that approximately 10%–30% of a spliced intron is 
preserved after the exosome and NMD digestion in cytoplasm 
with a relatively long half-life, indicating the cellular origin 
of native intronic miRNAs (Clement et al 1999).
Natural intronic miRNA biogenesis relies on the coupled 
interaction between nascent Pol-II-mediated pre-mRNA 
transcription and intron splicing/excision (Figure 1), which 
take place within certain nuclear regions proximal to genomic 
perichromatin (Ghosh and Garcia-Blanco 2000; Lin and Ying 
2004). In eukaryotic cells, gene transcription is mediated 
by Pol-II, and the resulting precursor mRNA (pre-mRNA) 
consists of four major components: 5’-untranslated region 
(UTR), protein-coding exon, noncoding intron and 3’-UTR. 
Broadly speaking, both 5’- and 3’-UTR can be seen as a kind 
of intron extension. Introns occupy the largest proportion of 
the noncoding sequences in the pre-mRNA. Each intron can 
Figure 1 Biogenesis of native intronic microRNA (miRNA). Intronic miRNA is co-transcribed within a precursor messenger RNA (pre-mRNA) by eukaryotic type-II RNA 
polymerases (Pol-II) and cleaved out of the pre-mRNA by RNA splicing. While the exons are ligated to form a mature messenger RNA (mRNA) for protein synthesis, the 
spliced intron(s) with a high secondary structure (ie, hairpin and/or stem-loop) is further processed into mature miRNA capable of triggering post-transcriptional gene silencing 
(PTGS) effects, such as RNA interference (RNAi).Clinical, Cosmetic and Investigational Dermatology 2008:1 22
Wu et al
range up to 30 kilobases and is excised out of the pre-mRNA 
during RNA splicing executed by intracellular spliceosomes. 
Subsequently, some of the intron-derived RNA fragments are 
further processed to form microRNA (miRNA) derivative 
molecules, which can effectively silence their respec-
tive targeted genes through an RNA interference (RNAi)-like 
mechanism. Exons, on the other hand, are ligated together to 
form a mature mRNA for protein synthesis.
Differences between miRNA 
and siRNA biogenesis pathways
We have demonstrated that effective mature miRNAs 
can be generated from the introns of vertebrate genes, of 
which the biogenetic process is different from those of 
siRNA and intergenic miRNA (Lin et al 2003; Lin et al 
2005). Figure 2 compares the native biogenesis and RNAi 
mechanisms among siRNA, intergenic (exonic) miRNA 
and intronic miRNA. Presumably, an siRNA is formed by 
two perfectly complementary RNAs transcribed by two 
reversely positioned promoters from one DNA template; 
these complementary RNAs are then hybridized and 
further processed into 20–25-bp duplexes by RNaseIII 
endoribonucleases, namely Dicer. Different from this 
siRNA model, the biogenesis of intergenic miRNA, eg, 
lin-4 and let-7, involves a long noncoding precursor RNA 
transcript (pri-miRNA), which is directly transcribed from 
a Pol-II or Pol-III RNA promoter, whereas intronic miRNA 
is co-transcribed with its encoding gene by only Pol-II 
and released after RNA splicing as a spliced intron. The 
spliced intron then serves as a pri-miRNA for processing 
into an intronic precursor miRNA (pre-miRNA) or a multi-
pre-miRNA cluster. In the cell nucleus, the pri-miRNA is 
further excised by either Drosha-like RNases (for intergenic 
miRNA) or spliceosomal components (for intronic miRNA) 
Figure 2 Comparison of various biogenesis and PTGS mechanisms among siRNA, intergenic (exonic) miRNA and intronic miRNA. SiRNA is formed by annealing of two 
perfectly complementary short RNAs transcribed from two opposite promoters (remains to be determined), and then further processed into 19–22 bp double-stranded 
duplexes by RNaseIII-familial endonucleases, Dicer. Intergenic (exonic) miRNA, eg, lin-4 and let-7, is directly transcribed as a long single-strand noncoding RNA precursor 
(pri-miRNA), probably by either a Pol-II or a Pol-III RNA promoter, whereas intronic miRNA is mainly transcribed by the Pol-II promoter of its encoded gene and co-existed 
within the intron region of the encoded gene transcript (pre-mRNA). After pre-mRNA splicing, the spliced intron functions as a pri-miRNA to form intronic miRNA. In the 
nucleus, the pri-miRNA is excised by either a Drosha RNase (intergenic miRNA) or spliceosomal/NMD components (intronic miRNA) to form hairpin-like miRNA precursors 
(pre-miRNA) and then exported to cytoplasm for further processing by Dicer* to form mature miRNAs. The Dicers for siRNA and miRNA pathways may be different. For 
instance, some spliceosomal/NMD components are likely involved in the maturation of intronic miRNA but not siRNA.  All three small regulatory RNAs are ﬁ  nally incorporated 
into a RNA-induced silencing complex (RISC), which contains either strand of siRNA or the single-strand of miRNA. The effect of miRNA is considered to be more speciﬁ  c 
and less adverse than that of siRNA because only one strand is involved. On the other hand, siRNAs primarily trigger mRNA degradation, whereas miRNAs can induce either 
mRNA degradation or translational suppression, depending on the sequence complementarity to their targeted gene transcripts.Clinical, Cosmetic and Investigational Dermatology 2008:1 23
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to form a hairpin-like stem-loop precursor or a cluster 
of multiple stem-loop structures, termed pre-miRNA, 
and then exported to cytoplasm for ﬁ  nal processing into 
mature miRNA by a miRNA-associated Dicer (Dicer*) 
(Lee et al 2003). Subsequently, all three small regulatory 
RNAs are incorporated into a RNA-induced silencing 
complex (RISC), which contains either strand of siRNA 
or the mature strand of miRNA. The Dicers and RISCs for 
siRNA and miRNA pathways are known to be different 
(Tang 2005). For example, some enzymes of the nonsense-
mediated decay (NMD) system may play the role of Dicer* 
in the mechanism of intronic miRNA maturation. As a 
result, the effect of miRNA is generally more speciﬁ  c and 
less adverse than that of siRNA because only one strand 
is involved. On the other hand, siRNAs primarily trigger 
mRNA degradation, whereas miRNAs can induce either 
mRNA degradation or suppression of protein synthesis, or 
both, depending on the sequence complementarity to their 
targeted gene transcripts. Because the intronic miRNA 
pathway is tightly regulated by multiple intracellular 
surveillance systems, such as Pol-II transcription, RNA 
splicing, exosomal digestion and NMD processing, the 
gene silencing effects of intronic miRNA are considered to 
be more effective, speciﬁ  c and safer than those of siRNA 
and intergenic miRNA (Lin et al 2008).
Development of miRNA-based 
gene silencing agents
Based on the intronic RNA splicing and processing mecha-
nisms (Figures 3A and 3B), we have designed and developed 
a Pol-II-mediated recombinant gene expression system con-
taining at least a splicing-competent intron, namely SpRNAi, 
capable of inhibiting the EGFP gene with high complemen-
tarity to the intron sequence. The SpRNAi is co-transcribed 
with the precursor mRNA (pre-mRNA) of the recombinant 
gene by Pol-II RNA polymerases (P) and cleaved out of 
the pre-mRNA by RNA splicing. Subsequently, the spliced 
SpRNAi is further processed into mature gene silencing 
agents, such as shRNA and miRNA, capable of triggering 
RNAi-related gene silencing. After intron removal, the exons 
of the recombinant gene transcript are linked together to 
form a mature mRNA molecule for translational synthesis 
of a marker or functional protein.
As shown in Figure 3A, the essential components of the 
SpRNAi intron include several consensus nucleotide ele-
ments, consisting of a 5’-splice site, a branch-point motif 
(BrP), a poly-pyrimidine tract (PPT), and a 3’-splice site. In 
addition, a hairpin RNA-like pre-miRNA sequence is inserted 
inside the SpRNAi intron located between the 5’-splice site 
and the branch-point motif (BrP). This portion of the intron 
normally forms a lariat structure during RNA splicing and 
processing. We have observed that spliceosomal U2 and 
U6 snRNPs, both helicases, are involved in the unwinding 
and excision of the lariat RNA fragment into pre-miRNA; 
however, the detailed processing remains to be elucidated. 
Further, the 3’-end of the SpRNAi construct contains a mul-
tiple translational stop codon region (T codon) in order to 
increase the accuracy of intronic RNA splicing and NMD 
processing. When presented in a cytoplasmic mRNA, this 
T codon will signal the activation of the nonsense-mediated 
decay (NMD) pathway to degrade any unstructured RNA 
accumulation in the cell. However, the highly secondary 
structured hairpin RNA and pre-miRNA insert will be 
preserved for further Dicer cleavage, so as to form mature 
siRNA and miRNA, respectively. Moreover, for intracellular 
expression, we manually incorporate the SpRNAi construct in 
the DraII restriction site of a red ﬂ  uorescent protein (RGFP) 
gene isolated from mutated chromoproteins of the coral reef 
Heteractis crispa, so as to form a recombinant SpRNAi-RGFP 
gene. The cleavage of RGFP at its 208th nucleotide site by 
the restriction enzyme DraII generates an AG–GN nucleotide 
break with three recessing nucleotides in each end, which 
will form 5’- and 3’-splice sites respectively after the SpRNAi 
insertion. Because this intronic insertion disrupts the struc-
ture of a functional RGFP protein, which can be recovered 
by intron splicing, we can determine the release of intronic 
shRNA/miRNA and RGFP-mRNA maturation through the 
appearance of red RGFP around the affected cells. The RGFP 
gene also provides multiple exonic splicing enhancers (ESEs) 
to increase RNA splicing accuracy and efﬁ  ciency.
In this intronic miRNA expression system (Figure 3B), 
we provide a genetic engineering method for using synthetic 
RNA splicing and processing elements, such as 5’-splice site, 
branch-point motif (BrP), poly-pyrimidine tract (PPT), and 
3’-splice site, to form an artiﬁ  cial SpRNAi intron containing 
at least a desired RNA insert for antisense RNA, small hair-
pin RNA (shRNA) and/or microRNA (miRNA) production. 
A DNA synthesizer can chemically produce and link these 
elements. Alternatively, the linkage of these elements can 
be achieved by enzymatic restriction and ligation. The intron 
so obtained can be used directly for transfection into cells of 
interest or further incorporated into a cellular gene for co-
expression along with the gene transcript (ie, pre-mRNA) 
by Pol-II. During RNA splicing and mRNA maturation, 
the desired RNA insert will be excised and released by 
intracellular spliceosome, exosome and NMD mechanisms Clinical, Cosmetic and Investigational Dermatology 2008:1 24
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and then triggers a desired gene silencing effect on speciﬁ  c 
gene transcripts with high complementarity to the inserted 
RNA sequence, while the exons of the recombinant gene 
transcript are linked together to form mature mRNA for 
expression of a desirable gene function, such as translation 
of a reporter or marker protein selected from the group of 
red/green ﬂ  uorescent protein (RGFP/EGFP), luciferase, 
lac-Z, and their derivative homologues. The presence of the 
reporter/marker protein is useful for signaling the produc-
tion of the inserted shRNA/miRNA molecules in treated 
cells, thus facilitating the identiﬁ  cation of the desired gene 
silencing/RNAi effects.
In accordance with the biogenesis of intronic miRNA, 
mature mRNA formed by the linkage of exons can also be 
useful in conventional gene therapy to replace impaired or 
missing gene function, or to increase speciﬁ  c gene expres-
sion. Alternatively, this method provides novel composi-
tions and means for inducing cellular production of gene 
silencing molecules through intronic RNA splicing and 
processing mechanisms to elicit either antisense-mediated 
Figure 3 Structural composition of the SpRNAi-incorporated recombinant RGFP gene (SpRNAi-RGFP) in an expression-competent vector (A), and the strategy (B) of using this 
composition to generate manmade microRNA (miRNA), mimicking the biogenesis mechanism of natural intronic miRNAs. In vivo tests of the SpRNAi-RGFP gene composition 
against a targeted green EGFP gene in Tg(actin-GAL4:UAS-gfp) zebraﬁ  sh showed a signiﬁ  cant knockdown of over 85% of the EGFP gene expression, as determined by western 
blot analyses (C). The intron-derived anti-EGFP miRNA and its spliced precursor were clearly observed on a 1% formaldehyde agarose gel electrophoresis after northern 
blotting (D).Clinical, Cosmetic and Investigational Dermatology 2008:1 25
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gene knockout or RNA interference (RNAi) effects, which 
are useful for inhibiting targeted gene function. The intron-
derived gene silencing molecules so obtained may include 
antisense RNA, ribozyme, short temporary RNA (stRNA), 
double-stranded RNA (dsRNA), small interfering RNA 
(siRNA), tiny noncoding RNA (tncRNA), short hairpin RNA 
(shRNA), microRNA (miRNA), and RNAi-associated pre-
cursor RNA constructs (pri-/pre-miRNA). The use of these 
intronic RNA-derived gene silencing agents is a powerful 
tool for targeting and silencing unwanted genes selected 
from the group consisting of pathogenic transgenes, viral 
genes, mutant genes, oncogenes, disease-related small 
RNA genes and any other types of protein-coding as well 
as noncoding genes.
Using this novel Pol-II-mediated SpRNAi-RGFP expres-
sion system, we have successfully generated mature shRNA 
and miRNA molecules with full gene silencing capacity in 
vitro in human prostate cancer (LNCaP), human cervical 
cancer (HeLa) and rat neuronal stem (HCN-A94-2) cells as 
well as in vivo in zebraﬁ  sh, chicken and mouse (Lin and Ying 
2006; Lin et al 2006). We have tested different pre-miRNA 
insert constructs targeting against green EGFP and other 
cellular gene expression in zebraﬁ  sh and various human 
cell lines, and have learned that effective gene silencing 
miRNAs are derived from the 5’-proximity of the intron 
sequence between the 5’-splice site and the branching point. 
As shown in Figure 3C, a strong gene silencing effect was 
observed only in the transfection of anti-EGFP pre-miRNA 
insert (lane 4), whereas no effect could be detected in those 
of other inserts indicated by lanes from left to right: 1, blank 
vector control (Ctl); 2, pre-miRNA insert targeting HIV-p24 
(mock); 3, antisense EGFP insert without the hairpin loop 
structure (anti); and 5, reverse pre-miRNA sequence which 
was completely complementary to the anti-EGFP pre-
miRNA (miR*). No effect was detected on off-target genes, 
such as marker RGFP and housekeeping β-actin, suggest-
ing that such an intronic miRNA-mediated gene silencing 
effect is highly target-speciﬁ  c. To conﬁ  rm the role of RNA 
splicing in this intronic RNAi effect, we further tested three 
different SpRNAi-RGFP expression systems as shown in 
Figure 3D: 1, vector expressing intron-free RGFP without 
any pre-miRNA insert; 2, vector expressing RGFP with an 
intronic anti-EGFP pre-miRNA insert; and 3, vector similar 
to the 2 construct but with a defective 5’-splice site in the 
SpRNAi intron. As a result, northern blotting revealed that 
mature miRNAs were released only from the spliced intron 
of the vector 2 construct, which was exactly identical to the 
SpRNAi vector construct with the anti-EGFP pre-miRNA 
insert in Figure 3C. Thus, RNA splicing is required for 
intronic miRNA biogenesis.
Evaluation of natural antityrosinase 
miRNA agents
We have adopted the proof-of-principle design of the 
SpRNAi-RGFP expression system and use it for developing 
novel cosmetic products for skin care. In this new approach, 
we apply skins a nonnaturally occurring intron capable 
of being processed into hairpin-like precursor microRNA 
(pre-miRNA) molecules by the skin cells and thus inducing 
speciﬁ  c gene silencing effects on epidermal pigment-related 
genes and/or aging-causing genes. In this case, the RNA 
splicing- and processing-generated gene silencing molecule 
is the hairpin-like pre-miRNA insert located within the intron 
area of the recombinant gene and was capable of silencing 
a targeted gene, such as tyrosinase (Tyr), hyaluronidase 
(Hyal), hyaluronan receptors CD44 and CD168, and other 
pigmentation-related and/or aging-related genes and onco-
genes. Alternatively, such a pre-miRNA insert can also be 
artiﬁ  cially incorporated into the intron region of a cellular 
gene in the skin. In general, this kind of intronic insertion 
technology includes plasmid-like transgene transfection, 
homologous recombination, transposon delivery, jumping 
gene integration and retroviral infection.
In the present design, the recombinant SpRNAi-RGFP 
gene expresses an intronic insert construct reminiscent of 
a hairpin-like pre-mRNA structure. The recombinant gene 
consists of an exon and an intron. The exon is ligated after 
RNA splicing to form a functional mRNA and protein for 
identiﬁ  cation of the intronic RNA release, while the intron 
is spliced out of the recombinant gene transcript and further 
processed into the desired intronic RNA molecule that func-
tions as a gene silencing effector. These desired intronic RNA 
molecules may comprise a hairpin-like stem-loop structure 
containing a sequence motif homologous to 5’-GCTAAGC-
CAG GC-3’ or 5’-GCCTGGCTTA GC-3’, which facilitates 
not only accurate excision of the desired RNA molecule 
out of the intron but also nuclear exportation of the desired 
RNA molecule to the cytoplasm. Also, the stem-arms of 
these intron-derived RNA molecules contain homology or 
complementarity, or both, to a targeted gene or a coding 
sequence of the targeted gene transcript. The homologous 
or complementary sequences of the desired RNA molecules 
are sized from approximately 18 to 27 nucleotide bases. The 
homology and/or complementarity rate of the desired intronic 
RNA molecule to the targeted gene sequence is ranged from 
approximately 30%∼100%, more preferably 35%∼49%, for Clinical, Cosmetic and Investigational Dermatology 2008:1 26
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a desired hairpin-like intronic RNA and 90%∼100% for a 
linear intronic RNA molecule.
In addition, the 5’-end of the nonnaturally occurring 
intron contains a donor splice site homologous to 5’-
GTAAGAGK-3’ motifs, while its 3’-end is an acceptor 
splice site that is homologous to 5’-GWKSCYRCAG-3’ 
motifs. Moreover, a branch point sequence is located 
between the 5’- and 3’-splice sites, containing homology 
to 5’-TACTWAY-3’ motifs. The adenosine “A” nucleo-
tide of the branch-point sequence forms a part of (2’–5’)-
linked lariat intron RNA by cellular (2’–5’)-oligoadenylate 
synthetases and spliceosomes in almost all spliceosomal 
introns. Furthermore, a poly-pyrimidine tract is closely 
located between the branch-point and 3’-splice site, 
containing a high T or C content oligonucleotide sequence 
homologous to either 5’-(TY)m(C/−)(T)nS(C/−)-3’ or 
5’-(TC)nNCTAG(G/−)-3’ motifs. The symbols of “m” and 
“n” indicate multiple repeats 1; most preferably, the m 
number is equal to 1∼3 and the n number is equal to 7∼12. 
The symbol “–” refers to an empty nucleotide in the sequence. 
There are also some linker nucleotide sequences for the con-
nection of all these intron components. By deﬁ  nition, the 
symbol W refers to an adenine (A) or thymine (T)/uracil (U), 
the symbol K refers to a guanine (G) or thymine (T)/uracil 
(U), the symbol S refers to a cytosine (C) or guanine (G), the 
symbol Y refers to a cytosine (C) or thymine (T)/uracil (U), 
the symbol R refers to an adenine (A) or guanine (G), and 
the symbol N refers to an adenine (A), cytosine (C), guanine 
(G) or thymine (T)/uracil (U).”
Based on the above design, we have tested an optimized 
SpRNAi-RGFP gene construct expressing either anti-Tyr or 
anti-Hyal pre-miRNA directed against the pigmentation-
related gene Tyr or aging-related gene Hyal in mouse skins. 
These pre-miRNAs target a highly conserved region (98% 
homology) in both human Tyr and mouse Hyal genes. In 
nature, there are 54 native miRNAs capable of targeting 
human tyrosinase (Tyr; 2082 bp) for pigmentation gene 
silencing, including mir-1, mir-15a, mir-16, mir-31, mir-
101, mir-129, mir-137, mir-143, mir-154, mir-194, mir-195, 
mir-196b, mir-200b, mir-200c, mir-206, mir-208, mir-214, 
mir-221, mir-222, mir-292-3p, mir-299-3p, mir-326, mir-
328, mir-381, mir-409-5p, mir-434-5p, mir-450, mir-451, 
mir-452, mir-464, mir-466, mir-488, mir-490, mir-501, 
mir-522, mir-552, mir-553, mir-570, mir-571, mir-582, mir-
600, mir-619, mir-624, mir-625, mir-633, mir-634, mir-690, 
mir-697, mir-704, mir-714, mir-759, mir-761, mir-768-5p, 
and mir-804. According to the miRNA-target database of the 
miRBase::Sequences program (http://microrna.sanger.ac.uk), 
all these anti-Tyr miRNAs are directed against a region within 
the ﬁ  rst 300 nucleotides of the Tyr gene transcript (NCBI 
accession number NM000372). On the other hand, there are 
9 native miRNAs capable of targeting hyaluronidase (Hyal; 
2518 bp; NCBI accession number NM007312) for aging gene 
silencing, including mir-197, mir-349, mir-434-5p, mir-549, 
mir-605, mir-618, mir-647, mir-680, mir-702, and mir-763. 
Among these native miRNAs, mir-434-5p is the only one that 
targets both Tyr and Hyal genes in human and it is also one of 
the most efﬁ  cient miRNAs targeting the least off-target genes 
other than Tyr and Hyal. However, because almost all native 
miRNAs target several to over ﬁ  fty cellular genes and they 
tend to bind with some of the target genes more strongly than 
others, the use of these native miRNAs is likely not speciﬁ  c 
and safe enough for the purpose of skin care.
To test the feasibility of miRNA-mediated skin whit-
ening, we utilized an SpRNAi-RGFP expression vector to 
express native pre-mir-434-5p in mouse skin. As shown in 
Figure 4, patched albino (white) skins of melanin-knockdown 
mice (W-9 black) were observed after a daily intra-cutaneous 
(i.c.) injection of the pre-mir-434-5p expression vector 
(50 μg) for four times (total 200 μg). Tyr, a type-I mem-
brane protein and copper-containing enzyme, catalyzes the 
critical and rate-limiting step of tyrosine hydroxylation in 
the biosynthesis of melanin (black pigment) in skins and 
hairs; thus, the silencing of Tyr expression will result in a 
great loss of skin/hair pigments. Approximately two weeks 
after the ﬁ  rst i.c. injection, we could clearly observe that the 
skin and hair pigments were signiﬁ  cantly lost only in mice 
transfected with the pre-mir-434-5p. In contrast, the blank 
control and the transfection of a Pol-III (U6)-transcribed 
siRNA agent against the same Tyr sequence presented no sig-
niﬁ  cant effects. Northern blot analyses using mRNAs isolated 
from the hair follicles of the pre-mir-434-5p-transfected 
mice showed a markedly reduction of the Tyr expression 
(76.1% ± 5.3%) two days post-transfection, whereas mild, 
nonspeciﬁ  c degradation of random gene transcripts was 
detected in the siRNA-transfected skins (seen from the 
smearing patterns of both house-keeping control GAPDH 
and targeted Tyr mRNAs). Since Grimm et al have reported 
that high concentrated siRNA/shRNA can over-saturate the 
cellular miRNA pathway and cause global mRNA degrada-
tion (Grimm et al 2006), our results indicate that the siRNA 
pathway is incompatible with the native miRNA pathway 
in skin cells. Thus, the use of miRNA likely will provide 
a more effective, compatible and safe means for skin care. 
However, because the native mir-434-5p is able to silence 
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LYPLA2 and Hyal, its off-target gene silencing effects remain 
to be determined.
Re-design of mir-434-5p for skin 
whitening use in human
In order to improve the target-speciﬁ  city and safety of anti-
Tyr miRNA agents, we have re-designed the seed sequence 
of the mir-434-5p to form a highly matched region binding 
to either Tyr nucleotides 3–25 (miR-Tyr) or Hyal nucleotides 
459–482 (miR-Hyal). The pre-miRNA insert sequence 
for pre-miR-Tyr is 5’-GTCCGATCGT CGCCCTACTC 
TATTGCCTAA GCCGCTAAGC CAGGCGGCTT 
AGGCAATAGA GTAGGGCCGA CGCGTCAT-3’, which 
forms a hairpin-like RNA after splicing and can be further 
processed into a mature miR-Tyr microRNA (miRNA) 
sequence containing or homologous to 5’-GCCCTACTCT 
ATTGCCTAAG CC-3’. Alternatively, the sequence for 
pre-miR-Hyal is 5’-GTCCGATCGT CAGCTAGACA 
GTCAGGGTTT GAAGCTAAGC CAGGCTTCAA 
ACCCTGACTG TCTAGCTCGA CGCGTCAT-3’, which 
forms a different kind of hairpin-like RNA after splicing 
and is further processed into a mature miR-Hyal miRNA 
sequence containing or homologous to 5’-AGCTAGACAG 
TCAGGGTTTG AA-3’. Although both pre-miR-Tyr and 
pre-miR-Hyal constructs were re-designed based on the same 
mir-434-5p backbone and mir-302 stem-loop, the mature 
miR-Tyr and miR-Hyal were shown to be totally different 
from each other. As shown in Figure 5, the transfective 
expressions of miR-Tyr and miR-Hyal in mouse skins spe-
ciﬁ  cally knocked down the targeted Tyr (reduction 90%) 
and Hyal genes (reduction 67%), respectively, without 
any crossover off-target effect. The expression levels of 
mature miR-Tyr and miR-Hyal microRNAs were directly 
measured by northern blot analyses, while the knockdown 
rates of the targeted Tyr and Hyal proteins were assessed by 
western blot analyses.
After understanding the optimized gene silencing effects 
of the re-designed miR-Tyr and miR-Hyal miRNAs, we 
continued to test their efﬁ  cacy, target speciﬁ  city and safety 
in human skins. For efﬁ  cient vector transfection into the 
Figure 4 Effects of miRNA-mediated tyrosinase (Tyr) gene silencing on the depigmentation of mouse skins and hairs. Targeted gene silencing in epidermal tissues was shown 
to be feasible using the ectopic transfection of a recombinant SpRNAi-RGFP gene vector expressing the native mir-434 pre-miRNA. Subcutaneous transfection of mir-434-5p 
induced a strong and speciﬁ  c gene silencing effect on Tyr but not house-keeping GAPDH expression, whereas transfection of a U6 promoter-driven siRNA against the same 
Tyr sequence resulted in nonspeciﬁ  c RNA degradation of both Tyr and GAPDH gene transcripts. Because Tyr plays an essential role in melanin (black pigment) production, a 
successful Tyr gene silencing effect can be manifested by the signiﬁ  cant loss of black color in mouse skins and hairs. The circles indicate the location of i.c. injections. Small 
windows show the northern blotting of Tyr mRNA levels in local hair follicles, conﬁ  rming the gene silencing effect of mir-434-5p on Tyr expression.Clinical, Cosmetic and Investigational Dermatology 2008:1 28
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human epidermal cell layers, a 1 μg/ml SpRNAi-RGFP 
vector solution was prepared by mixing 100 μg of the puriﬁ  ed 
SpRNAi-RGFP vector in 1 ml of autoclaved ddH2O with 
99 ml of 100% DNase-free glycerin (or glycerol). DNase-
free glycerin was used to encapsulate miR-Tyr for deep 
skin delivery and cell membrane penetration. This formed 
the major ingredient base for skin whitening and lightening 
products. Based on this, more other cosmetic ingredients 
could be added to increase the color, fragrance, effectiveness 
and/or stability of the ﬁ  nal cosmetic products. As shown in 
Figure 6A, Asian male arm skins were treated with 2 ml of 
this major ingredient base expressing either miR-Tyr (right) 
or empty SpRNAi-RGFP vector alone (glycerin control, left). 
The whitening effect of the miR-Tyr treatment on human 
skins (loss of the black pigment–melanin) was clearly 
observed within three days after two treatments per day.
Next, a primary skin cell culture was obtained by 
trypsin-dissociated skin explants from the tested donor with 
personal consent. The SpRNAi-RGFP vector transfection 
(ﬁ  nal 6 μg/ml) in the primary skin culture was performed 
using FuGene liposomal reagent (Roche Biochemicals, 
Indianapolis, IN), as described previously (Lin et al 2003; 
Lin et al 2006). Figure 6B shows that western blot analyses 
of the loss of the targeted tyrosinase proteins and its substrate 
melanin were statistically signiﬁ  cant (p  0.001). The reduc-
tion levels of Tyr and its substrate melanin in skins were 
proportional to the treated concentrations of the miR-Tyr 
expression vector, suggesting a positive correlation between 
the increase of the miR-Tyr treatment and the loss of the 
targeted Tyr proteins and its substrate melanin. No effect 
was observed in other treatments, such as SpRNAi-RGFP 
vector alone (glycerin control) and an SpRNAi-RGFP vector 
expressing an anti-EGFP pre-miRNA (miR-gfp). At 1 μg/ml 
of the miR-Tyr expression vector transfection, the optimal 
gene silencing rates were approximately 55%–60% for Tyr 
and 30%–45% for melanin, while the expression of nontarget 
house-keeping control ß-actin was not affected by miR-
Tyr treatment. Taken together, these results demonstrated 
the high target-speciﬁ  city of our re-designed manmade 
miRNA agents.
Figure 6C further showed that the skin melanin levels 
were signiﬁ  cantly reduced as shown in bright-ﬁ  eld (BF) 
Figure 5 Effects of Tyr and Hyal gene silencing on skin pigmentation in mice. The speciﬁ  city of tyrosinase (Tyr) gene silencing was markedly improved, using a man-made anti-Tyr 
pre-miRNA (miR-Tyr) expressed by the recombinant SpRNAi-RGFP gene vector in mouse skins, showing a much higher target-speciﬁ  c and less off-target silencing effect on the 
targeted Tyr gene expression. Neither off-target (hyaluronidase) nor housekeeping (ß-actin) genes were affected by miR-Tyr treatment.Clinical, Cosmetic and Investigational Dermatology 2008:1 29
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photographs of the primary skin cell culture (upper panels), 
while melanin (black dots around the cell nuclei) is highly 
expressed in normal skin cells without miR-Tyr treatment 
(ie, blank and glycerin only). The miR-Tyr-treated skin cells 
showed very limited melanin accumulation, demonstrating 
an effective skin-whitening effect in vivo. In regard to this 
loss of skin melanin, the targeted tyrosinase expression was 
concurrently reduced in the miR-Tyr-treated skin cells, 
as determined by immunocytochemical (ICC) staining analy-
sis (Figure 6C, lower panels). According to these results, the 
re-designed miR-Tyr microRNA effectively knocked down 
the expression of Tyr proteins and successfully blocked 
melanin production in human skins in vivo.
Microarray analyses of target 
speciﬁ  city and safety
After the efﬁ  cacy of miR-Tyr-mediated gene silencing was 
established in human skins, we applied human genome 
microarray analyses (Human GeneChip U133A&B arrays, 
Affymetrix, Santa Clara, CA) to assess the changes of 
approximately 32,668 human gene expression patterns 
in miR-Tyr-transfected and control primary skin cell cul-
tures. As shown in Figure 7A (left), microarray analyses 
in nontreated (miR–) versus miR-Tyr-transfected (miR+) 
primary skin cell cultures showed that only two cellular 
genes, Tyr and its associated TRPI, whose expression levels 
were altered more than 1.5-fold (50% change of gene 
expression; Figure 7B), indicating that the miR-Tyr-mediated 
gene silencing effect is highly speciﬁ  c to the targeted Tyr. 
Furthermore, no gene related to either cytotoxicity or inter-
feron-mediated PKR/2-5A pathway was affected, suggesting 
that this gene silencing effect is safe for skin care treatments. 
We have also used northern blot analyses to compare and 
assess the gene expression levels of the microarray-identiﬁ  ed 
genes (Figure 7C), conﬁ  rming the results of Figures 7A 
and 7B. Furthermore, the correlation coefﬁ  ciency (CC) 
rate clearly indicated that a high 99.8% population of the 
32,668 tested human genes remained unchanged in the miR-
Tyr-transfected (miR+) cells, compared to a signiﬁ  cantly 
lower 77.6% CC rate in the mir-434-5p-transfected cells 
(Figure 7A, right). This indicates that the expression pat-
terns of as few as 65 cellular genes were altered in the cells 
transfected with the re-designed miR-Tyr. On the other hand, 
over 7,317 genes might be changed in the cells transfected 
with the native mir-434-5p. Since it is known that almost all 
native miRNAs target multiple cellular genes due to their 
mismatched stem-arms, our present study demonstrates that 
the re-design of these miRNA stem-arm regions is necessary 
Figure 6 Effects of Tyr gene silencing on skin pigmentation in human skins. Human trials showed that over 50% of the Tyr expression was suppressed by the re-designed 
miR-Tyr, conﬁ  rming the results of Figure 5 but in the human arm skins (A) and primary skin cell cultures (B and C), as determined by western blotting and immunocytochemical 
(ICC) staining analyses.Clinical, Cosmetic and Investigational Dermatology 2008:1 30
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for increasing the safety and efﬁ  ciency of these miRNAs used 
in cosmetic applications.
Materials and methods
Construction of SpRNAi-containing 
recombinant transgene (SpRNAi-RGFP)
Synthetic nucleic acid sequences used for generation of three 
different SpRNAi introns containing either sense-, antisense- 
or hairpin-EGFP insert were listed as follows: N1-sense, 
5’-pGTAAGAGGAT CCGATCGCAG GAGCGCACCA 
TCTTCTTCAA GA-3’; N1-antisense, 5’-pCGCGTCTTGA 
AGAAGATGGT GCGCTCCTGC GATCGGATCC 
TCTTAC-3’; N2-sense, 5’-pGTAAGAGGAT 
CCGATCGCTT GAAGAAGATG GTGCGCTCCT GA-3’; 
N2-antisense, 5’-pCGCGTCAGGA GCGCACCATC 
TTCTTCAAGC GATCGGATCC TCTTAC-3’; N3-sense, 
5’-pGTAAGAGGAT CCGATCGCAG GAGCGCACCA 
TCTTCTTCAA GTTAACTTGA AGAAGATGGT 
Figure 7 Human genome microarray analyses (Affymetrix human GeneChip U133A&B, CA) of altered gene expression patterns in the human primary skin cell cultures with 
or without miR-Tyr transfection. This procedure was performed to demonstrate the higher target-speciﬁ  city and lower off-target effect of the miR-Tyr compared to those 
of native microRNAs, such as mir-434-5p.Clinical, Cosmetic and Investigational Dermatology 2008:1 31
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GCGCTCCTGA-3’; N3-antisense, 5’-pCGCGTCAGGA 
GCGCACCATC TTCTTCAAGT TAACTTGAAG 
AAGATGGTGC GCTCCTGCGA TCGGATCCTC 
TTAC-3’; N4-sense, 5’-pCGCGTTACTA ACTGGTACCT 
CTTCTTTTTT TTTTTGATAT CCTGCAG-3’; 
N4-antisense, 5’-pGTCCTGCAGG ATATCAAAAA 
AAAAAGAAGA GGTACCAGTT AGTAA-3’. In addition, 
two exon fragments were generated by DraII restriction 
enzyme cleavage of a red ﬂ  uorescent RGFP gene at its 
208th nucleotide (nt) site and the 5’ fragment was further 
blunt-ended by T4 DNA polymerase. RGFP refers to a 
new red-shifted ﬂ  uorescent chromoprotein gene generated 
by insertion of an additional aspartate at the 69th amino 
acid (a.a.) site of HcRed1 chromoproteins from Heteractis 
crispa. (BD Biosciences, CA), developing less aggregate 
and almost twice intense far-red fluorescent emission 
at 570-nm. We also cleaved a pHcRed1-N1/1 plasmid 
(BD Biosciences, CA) with XhoI and XbaI restriction 
enzymes and puriﬁ  ed a full 769-bp RGFP gene fragment 
and a 3,934-bp empty plasmid separately isolated from 2% 
agarose gel electrophoresis.
Hybridization of N1-sense to N1-antisense, N2-sense 
to N2-antisense, N3-sense to N3-antisense and N4-sense 
to N4-antisense was separately performed by heating 
each complementary mixture of sense and antisense (1:1) 
sequences to 94 °C for 2 min and then 70 °C for 10 min 
in 1x PCR buffer (eg, 50 mM Tris-HCl, pH 9.2 at 25 °C, 
16 mM (NH4)2SO4, 1.75 mM MgCl2). Continuously, sequen-
tial ligation of either N1, N2 or N3 hybrid to the N4 hybrid 
was performed by gradually cooling the mixture of N1-N4, 
N2-N4 or N3-N4 (1:1) hybrids respectively from 50 °C to 
10 °C over a period of 1 hr, and then T4 ligase and relative 
buffer (Roche, IN) were mixed with the mixture for 12 hr at 
12 °C, so as to obtain introns for insertion into exons with 
proper ends. After the RGFP exon fragments were added 
into the reaction (1:1:1), T4 ligase and buffer were adjusted 
accordingly to reiterate ligation for another 12 hr at 12 °C. 
To clone the properly sized recombinant RGFP gene, 10 ng 
of the ligated nucleotide sequences were ampliﬁ  ed by PCR 
with a pair of RGFP-speciﬁ  c primers 5’-CTCGAGCATG 
GTGAGCGGCC TGCTGAA-3’ and 5’-TCTAGAAGTT 
GGCCTTCTCG GGCAGGT-3’ at 94 °C, 1 min, 52 °C, 
1 min and then 68 °C, 2 min for 30 cycles. The resulting 
PCR products were fractionated on a 2% agarose gel, and 
a ∼900-bp nucleotide sequences was extracted and puriﬁ  ed 
by a Gel Extraction kit (Qiagen, CA). The composition of 
this ∼900 bp SpRNAi-containing RGFP gene was further 
conﬁ  rmed by sequencing.
Since the recombinant SpRNAi-RGFP gene possesses 
an XhoI and an XbaI restriction site at its 5’- and 3’-end, 
respectively, it can be easily cloned into a vector with cohe-
sive ends to the XhoI and XbaI cloning sites. The vector must 
be a skin-compatible, expressing-competent organism or 
suborganism selected from the group consisted of plasmids, 
cosmids, jumping genes, transposons, adeno-associated viral 
and retroviral vectors. Moreover, since the insert within the 
intron is also ﬂ  anked with a PvuI and an MluI restriction 
site at its 5’- and 3’-end, respectively, we can remove and 
replace the insert with another different insert sequence pos-
sessing cohesive ends to the PvuI and MluI cloning sites. The 
inserted sequence is preferably a hairpin-like gene silencing 
effector containing high complementarity to a gene target 
selected from the group consisted of ﬂ  uorescent protein 
(GFP) genes, luciferase genes, lac-Z genes, viral genes, 
bacterial genes, plant genes, animal genes and human genes. 
The complementarity and/or homology rate between the 
gene-silencing effector insert and its targeted gene is ranged 
from about 30%–100%, more preferably 35%–49% for a 
hairpin-shRNA insert and 90%–100% for a sense-stRNA 
or antisense-siRNA insert.
Cloning of the SpRNAi-containing transgene 
into an expression-competent vector
We mixed the SpRNAi-RGFP gene with the linearized 
3,934-bp empty pHcRed1-N1/1 plasmid at 1:16 (w/w) ratio, 
cooled the mixture from 65 °C to 15 °C over a period of 
50 min, and then added T4 ligase and relative buffer accord-
ingly into the mixture for ligation at 12 °C for 12 hrs. This 
forms the SpRNAi-RGFP expression vector, which can 
be propagated in an E.coli DH5α LB culture containing 
50 μg/ml kanamycin (Sigma Chemical, St. Louis, MO). 
A positive clone was conﬁ  rmed by PCR with the RGFP-
speciﬁ  c primers at 94 °C, 1 min and then 68 °C, 2 min for 30 
cycles, and for further sequencing. For cloning into viral vec-
tors, the same ligation procedure was repeated except using an 
XhoI/XbaI-linearized pLNCX2 retroviral vector (BD). Since 
the insert within the SpRNAi intron was ﬂ  anked with a PvuI 
and a MluI restriction site at its 5’- and 3’-end, respectively, 
we could remove and replace the anti-EGFP shRNA insert 
with the miR-Tyr or miR-Hyal insert sequences possessing 
cohensive ends to the PvuI and MluI cloning sites.
Synthetic nucleic acid sequences used for generating 
various SpRNAi introns containing either miR-Tyr or 
miR-Hyal insert were listed as follows: miR-Tyr-sense, 
5’-GTCCGATCGT CGCCCTACTC TATTGCCTAA 
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GTAGGGCCGA CGCGTCAT-3’; miR-Tyr-antisense, 
5’-ATGACGCGTC GGCCCTACTC TATTGCCTAA 
GCCGCCTGGC TTAGCGGCTT AGGCAATAGA 
GTAGGGCGAC GATCGGAC-3’; and miR-Hyal-sense, 
5’-GTCCGATCGT CAGCTAGACA GTCAGGGTTT 
GAAGCTAAGC CAGGCTTCAA ACCCTGACTG 
TCTAGCTCGA CGCGTCAT-3’; miR-Hyal-antisense, 
5’-ATGACGCGTC GAGCTAGACA GTCAGGGTTT 
GAAGCCTGGC TTAGCTTCAA ACCCTGACTG 
TCTAGCTGAC GATCGGAC-3’. These inserts were 
formed via hybridization of miR-Tyr-sense to miR-Tyr-
antisense and miR-Hyal-sense to miR-Hyal-antisense, 
respectively. These miR-Tyr- and miR-Hyal-expressing 
vectors could be propagated in E.coli DH5α LB-culture 
containing either 50 μg/ml kanamycin (for pHcRed1-N1/1 
plasmid-based vector) or 100 μg/ml ampicillin (for pLNCX2 
viral vector). The propagated SpRNAi-RGFP vectors could be 
isolated and puriﬁ  ed using a Mini-prep or Maxi-prep Plasmid 
Extraction kit (Qiagen, CA), following the manufacturer’s 
suggestion. For pLNCX2 vectors, we also used a packaging 
cell line PT67 (BD) for producing infectious but replication-
incompetent virus. The transfected PT67 cells were grown 
in 1x DMEM medium supplemented with 10% fetal bovine 
serum with 4 mM L-glutamine, 1 mM sodium pyruvate, 
100 μg/ml streptomycin sulfate and 50 μg/ml neomycin 
(Sigma Chemical, MO) at 37 °C under 5% CO2. The titer of 
virus produced by PT67 cells was determined to be at least 
106 cfu/ml before transfection.
Vector transfection
For vector transfection into cultivated cells or mouse skins, 
we ﬁ  rst mixed the SpRNAi-RGFP expression plasmid vectors 
containing either anti-EGFP, miR-Tyr or miR-Hyal pre-
miRNA insert using FuGene reagent (Roche, IN), following 
the manufacturer’s suggestion. Thereafter, the mixtures were 
directly applied to the cultivated cells (ie, primary human 
skin culture) or mouse skins, respectively. Vectors containing 
an insert-free RGFP gene and an SpRNAi-RGFP gene with 
a pre-miRNA insert against the HIV gag-p24 gene were 
used as negative controls. Tissue or cell morphology and 
ﬂ  uorescence imaging was photographed at 0-, 24-, 48-, and 
72-hr time points after the ﬁ  rst transfection. For transfec-
tion to the human skins in vivo, a pre-made SpRNAi-RGFP 
vector solution was formed by mixing certain amounts 
(ie, 1–1000 μg) of the puriﬁ  ed  SpRNAi-RGFP vector with 
or without either anti-EGFP, miR-Tyr or miR-Hyal pre-
miRNA insert in 1 ml of autoclaved ddH2O with 99 ml 
of 100% DNase-free glycerin (or glycerol). This solution 
was then directly applied to the skins with gentle massage 
for 3 min.
Northern blot analysis
RNA (20 μg total RNA or 2 μg poly[A+] RNA) was 
fractionated on 1% formaldehyde-agarose gels and 
transferred onto nylon membranes (Schleicher and Schuell, 
Keene, NH). Synthetic probes complementary to either 
the 75-bp junction sequence ﬂ  anking between the RGFP 
5’-exon and the anti-EGFP pre-miRNA insert or miR-Tyr, or 
miR-Hyal, were labeled with the Prime-It II kit (Stratagene, 
La Jolla, CA) by random primer extension in the presence 
of [32P]-dATP (3000 Ci/mM, Amersham International, 
Arlington Heights, IL), and puriﬁ  ed with 10 bp-cutoff Micro 
Bio-Spin chromatography columns (Bio-Rad, Hercules, 
CA). Hybridization was carried out in the mixture of 50% 
freshly deionized formamide (pH 7.0), 5x Denhardt’s solu-
tion, 0.5% SDS, 4x SSPE and 250 mg/mL denatured salmon 
sperm DNA fragments (18 hr, 42 °C). Membranes were 
sequentially washed twice in 2x SSC, 0.1% SDS (15 min, 
25 °C), and once in 0.2x SSC, 0.1% SDS (45 min, 37 °C) 
before autoradiography.
SDS-PAGE electrophoresis 
and Western blot analysis
For detection of targeted proteins, isolated cells were rinsed 
with ice cold PBS after growth medium was removed, and 
then treated with the CelLytic-M lysis/extraction reagent 
(Sigma, MO) supplemented with protease inhibitors, 
Leupeptin, TLCK, TAME and PMSF, following manu-
facture’s recommendations. The lysates were incubated 
at room temperature on a shaker for 15 min, scraped into 
microtubes, and centrifuged for 5 min at 12,000 × g to pel-
let the cell debris. Supernatants that contain lysate proteins 
were collected and stored at −70 °C until use. Protein 
determinations were measured with SOFTmax software 
package on an E-max microplate reader (Molecular Devices, 
Sunnyvale, CA). Each 30 μg cell lysate was added into 
SDS-PAGE sample buffer either with (reduced) or without 
(unreduced) 50 mM DTT, and boiled for 3 min before being 
loaded onto 8% polyacylamide gels, while the reference lane 
was loaded with 2∼3 μl molecular weight markers (Bio-Rad). 
SDS-polyacrylamide gel electrophoresis was performed 
according to the standard protocols (Molecular Cloning, 
3rd ED). Protein fractionations were electroblotted onto a 
nitrocellulose membrane, blocked with Odyssey blocking 
reagent (Li-Cor Biosciences, Lincoln, NB) for 1∼2 hr at 
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detected using primary antibodies directed against EGFP 
(1:5,000; JL-8, BD), RGFP (1:10,000; BD), Tyr (1:2,000; 
Santa Crutz), or Hyal (1:2,000; Santa Crutz) incubated 
overnight at 4 °C. The protein blots were then rinsed 3 times 
with TBS-T and incubated with goat antimouse secondary 
antibody conjugated with Alexa Fluor 680 reactive dye 
(1:2,000; Molecular Probes) for 1 hr at room temperature. 
After three more TBS-T rinses, scanning and image analysis 
were completed with Li-Cor Odyssey Infrared Imager and 
Odyssey Software v.10 (Li-Cor).
Intronic mir-434-5p and miR-Tyr-mediated 
gene silencing in mouse skins in vivo
Patched albino (white) skins of melanin-knockdown mice 
(W-9 black strain) were created either by a succession of 
intra-cutaneous (i.c.) injection of an isolated SpRNAi-RGFP 
gene expression vector with the native mir-434-5p 
pre-miRNA insert for 4 days (total 200 μg) or by a direct skin 
infusion of a liposome-encapsulated SpRNAi-RGFP gene 
expression vector with the designed miR-Tyr pre-miRNA 
insert for two times per day for six days (total 240 μg). To 
generate the SpRNAi-RGFP gene expression vector with 
the native mir-434-5p pre-miRNA insert, we followed 
the same procedure as aforementioned, except using a 
synthetic mir-434-5p pre-miRNA for intronic insertion 
(ie, 5’-GTCCGATCGT CUCGACUCUG GGUUUGAACC 
AAAGCUCGAC UCAUGGUUUG AACCAUUACU 
UAAUUCGUGG UUUGAACCAU CACUCGACUC 
CUGGUUCGAA CCAUCCGACG CGTCAT-3’). For 
efﬁ  cient delivery into target tissues, the construct was 
mixed with a FuGene liposomal transfection reagent 
(Roche, IN).
Intronic miR-Tyr-mediated gene 
silencing in human skins
For efﬁ  cient vector transfection into the human multiple skin 
cell layers, a 1 μg/ml SpRNAi-RGFP vector solution is made 
by mixing 100 μg of the puriﬁ  ed SpRNAi-RGFP vector in 
1 ml of autoclaved ddH2O with 99 ml of 100% DNase-free 
glycerin (or called glycerol). DNase-free glycerin is used to 
encapsulate miR-Tyr for deep skin delivery and cell mem-
brane penetration. This forms the major ingredient base for 
our present skin whitening and lightening inventions. There-
after, one (left arm) of the author’s arm skins was directly 
treated with one 2 ml of the major ingredient base solution 
containing  SpRNAi-RGFP vector with (right side) or without 
(left side) miR-Tyr. The effect of miR-Tyr treatment on skin 
whitening (loss of the black pigment–melanin) was assessed 
three days after two single treatments per day.
Immunocytochemical (ICC) staining assay
An immunochemical staining kit was obtained from Imgenex 
(San Diego, CA) and used according to the manufacturer’s 
suggestion. Specimens were ﬁ  rst rinsed in PBS three times 
and incubated with Zeller’s solution (10 mM Tris, 100 mM 
MgCl2, 5% fetal calf serum, 1% BSA and 0.5% Tween-20, 
pH 7.4) for 30 min. They were then incubated with primary 
antibody (diluted in Zeller’s solution) overnight in a humidi-
ﬁ  ed chamber at 4 °C. Thereafter, the specimens were washed 
with TBST three times and incubated with secondary anti-
body for 2 hr, using biotinylated goat antirabbit or horse 
antimouse antibody as the secondary antibody (Chemicon, 
Temecula, CA). Specimens were then washed once with 
TBST and incubated with streptavidin-HRP as the tertiary 
antibody for 2 hrs and followed by PBT washings. The bound 
antibody was subsequently detected with DAB substrates and 
observed under a 100x microscope with whole ﬁ  eld scanning 
and recorded at 100x and 400x magniﬁ  cation (TE2000 
inverted microscopic quantitation system).
Microarray analysis
To prepare labeled probes for microarray hybridization, 
total RNAs (2 μg) were converted into double-stranded 
cDNAs, using a Superscript Choice system kit (Gibco/BRL, 
Gaithersburg, MD) with a modiﬁ  ed oligo(dT)24-T7 promoter 
primer, such as 5’-GGCCAGTGAA TTGTAATACG 
ACTCACTATA GGGAGGCGG-(dT)24-3’, following the 
manufacturer’s protocol. Double-stranded cDNAs were 
puriﬁ  ed by phenol/chloroform extractions, precipitated with 
ethanol, and resuspended at a concentration of 0.5 μg/μl in 
diethyl pyrocarbonate (DEPC)-treated ddH2O. Phase-Lock 
Gel (5’Prime →3’Prime, Inc., Boulder, CO) was used 
for all organic extractions to increase recovery. In-vitro 
transcription was performed with T7 RNA polymerase and 
with 1 μg of cDNA, 7.5 mM unlabeled ATP and GTP, 5 mM 
unlabeled UTP and CTP, and 2 mM biotin-labeled CTP and 
UTP (biotin-11-CTP, biotin-16-UTP, Enzo Diagnostics). 
Reactions were carried out for 4 hr at 37 °C, and cRNA was 
puriﬁ  ed by RNeasy spin columns (Qiagen, CA). A sample 
was separated on a 1% agarose gel to check the size range, 
and then μg of cRNA was fragmented randomly to an average 
size of 50 bases by heating at 94 °C for 35 min in 40 mM 
Tris-acetate, pH 8.0, 100 mM KOAc/30 mM MgOAc.
Sets of four oligonucleotide microarrays (GeneChip 
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total 32,668 genes were used for hybridization. Hybridizations 
were completed in 200 μl of AFFY buffer (Affymetrix) at 
40 °C for 16 hr with constant mixing. After hybridization, 
arrays were rinsed three times with 200 μl of 6x SSPE-T 
buffer (1 × 0.25 M sodium chloride/15 mM sodium phos-
phate, pH 7.6/1 mM EDTA/0.005% Triton) and then washed 
with 200 μl of 6x SSPE-T for 1 hr at 50 °C. The arrays 
were rinsed twice with 0.5x SSPE-T and washed with 0.5x 
SSPE-T at 50 °C for 15 min. Staining was done with 2 μg/ml 
streptavidin-phycoerythrin (Molecular Probes) and 1 mg/ml 
acetylated BSA (Sigma) in 6x SSPE-T (pH 7.6). The arrays 
were read at 7.5 μm with a confocal scanner (Molecular 
Dynamics) and analyzed with Affymetrix Microarray Suite 
version 4.0 software. The samples were normalized by using 
the total average difference between perfectly matched probe 
and the mismatched probe. The differential signals that were 
induced greater than 2-fold are collected.
Statistical analysis
Results were presented as mean ±SE. Statistical analysis 
of data was performed by one-way ANOVA. When main 
effects were signiﬁ  cant, the Dunnett’s post-hoc test was 
used to identify the groups that differed signiﬁ  cantly from 
the controls. For pairwise comparison between two treatment 
groups, the two-tailed student t test was used. For experi-
ments involving more than two treatment groups, ANOVA 
was performed followed by a post-hoc multiple range test. 
Probability values of p  0.05 were considered signiﬁ  cant. 
All p values were determined from two-tailed tests.
Conclusion
In summary, the utilization of intronic hairpin-like miRNA 
expression provides a potentially powerful and innovative 
strategy for human skin care, particularly for hyperpigmen-
tation and aging prevention. Under the same treatment in 
animal trials, Pol-II-directed intronic miRNA expression 
did not cause any detectable cytotoxicity, whereas Pol-III-
directed siRNAs induced nonspeciﬁ  c mRNA degradation as 
previously reported (Elbashir 2001; Lin and Ying 2001; Sledz 
et al 2003; Lin and Ying 2004). This underscores the fact that 
the intronic miRNA agent is effective, target-speciﬁ  c and safe 
for use in skin care. Because the intronic miRNA pathway is 
regulated by multiple intracellular surveillance systems, such 
as Pol-II transcription, RNA splicing, exosomal digestion 
and NMD processing, the gene silencing effect of intronic 
miRNA is considered to be most effective, speciﬁ  c and 
safest among all three currently known RNAi pathways. 
By utilizing the intronic miRNA expression strategy, 
many cosmetic applications can be designed and developed 
for skin care, offering more long-term effectiveness, better 
target-speciﬁ  city and higher safety in skin gene manipulation, 
which prevents the unspeciﬁ  c off-target cytotoxicity as 
commonly seen in the conventional siRNA methods.
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